These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22594170)

  • 1. [Nursing care for a child with recurrent neuroblastoma treated with immunotherapy].
    Mast C
    Kinderkrankenschwester; 2012 Apr; 31(4):142-4. PubMed ID: 22594170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunotherapy--nursing requirements--presentation of care in immunotherapy with monoclonal antibodies as a part of the treatment of metastasized neuroblastoma IV].
    Lehner C
    Kinderkrankenschwester; 1998 Nov; 17(11):476-80. PubMed ID: 9887744
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy shows promise in Phase III neuroblastoma trial.
    Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644467
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.
    Cheung NK; Kushner BH; Yeh SJ; Larson SM
    Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy with GD2 specific monoclonal antibodies.
    Cheung NK; Medof ME; Munn D
    Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
    [No Abstract]   [Full Text] [Related]  

  • 7. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma.
    Cheung NK; Miraldi FD
    Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
    Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
    Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
    [No Abstract]   [Full Text] [Related]  

  • 9. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
    Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Selfless Act.
    Cohn SL
    J Clin Oncol; 2015 Nov; 33(32):3834-5. PubMed ID: 26261250
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
    Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract]   [Full Text] [Related]  

  • 14. Contemporary therapeutic options for children with high risk neuroblastoma.
    Sterba J
    Neoplasma; 2002; 49(3):133-40. PubMed ID: 12097996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of genetically engineered monoclonal antibodies for cancer immunotherapy.
    Reisfeld RA
    Pigment Cell Res; 1992; Suppl 2():109-12. PubMed ID: 1409412
    [No Abstract]   [Full Text] [Related]  

  • 19. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    Klin Padiatr; 2005; 217(3):147-52. PubMed ID: 15858706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy].
    Horwacik I
    Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.